High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

Hepatitis C Clinical Trial

Official title:

A Comparative Study of High-dose Interferon Alfa-2a and Pegylated Interferon Alfa-2a for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00381953
• Other study ID #: HCV02-01
• Status: Completed
• Phase: Phase 3
• Start date: February 2003
• Est. completion date: July 2006

Study information

• Verified date: August 2021
• Source: Foundation for Liver Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Comparison of virological breakthrough/relapse rate after dose adjustments and sustained virological response rate will be assessed by the type of induction.

Description:

The purpose of this study is to compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCVRNA suppression of 360 mug peginterferon QW, 9 MU interferon daily or 4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment. Comparison of virological breakthrough/relapse rate after dose adjustments and sustained virological response rate will be assessed by the type of induction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: July 2006
• Est. primary completion date: April 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• chronic hepatitis C

• detectable serum HCV-RNA

• elevated serum ALT activity documented on at least two occasions within the past 12 months, with at least one during the 90 day screening period preceding the initiation of test drug dosing

• liver biopsy findings (during screening or within previous 12 months) consistent with active fibrosis (haemophiliacs are excluded from biopsies)

• compensated liver disease (Child-Pugh Grade A clinical classification)

• negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug

• all fertile males and females receiving ribavirin and their fertile or potentially fertile partners must be advised to use two forms of effective contraception (combined) during treatment and during the 6 months after end of treatment

Exclusion Criteria:

• history or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigator, unsuitable for the study

• women with ongoing pregnancy or breast feeding

• therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) <3 months prior to the first dose of study drug

• any investigational drug <6 weeks prior to the first dose of study drug positive test at screening for HBsAg, anti-HIV Ab history or other evidence of bleeding from esophageal varices, ascites, or other conditions consistent with decompensated liver disease (Child-Pugh Grade B or C clinical classification)

• Signs or symptoms of hepatocellular carcinoma

• history or other strong evidence of a medical condition associated with chronic liver disease other than HCV (e.g., primary hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures

• Hb <7.5 mmol/l in women or <8.6 mmol/l in men at screening

• any patient with an increased baseline risk for anaemia (e.g. thalassemia, spherocytosis, etc) or for whom anaemia would be medically problematic neutrophil count <1500 cells/mm3 or platelet count <80,000 cells/mm3 at screening

• serum creatinine level >1.5 times the upper limit of normal at screening

• history of severe psychiatric disease, especially depression

• history of a severe seizure disorder or current anticonvulsant use

• history of immunologically mediated disease

• history or other evidence of chronic pulmonary disease associated with functional limitation

• history of severe allergies

• history of symptomatic and/or significant cardiovascular disease

• poorly controlled diabetes mellitus

• history of major organ transplantation with an existing functional graft

• hyper- or hypothyroidism

• evidence of severe retinopathy

• evidence of drug abuse (including excessive alcohol consumption within one year before study entry

Related Conditions & MeSH terms

• Hepatitis C

Intervention

Drug:
• Peginterferon alfa-2a

• Interferon alfa-2a

• Ribavirin

Locations

Country	Name	City	State
Netherlands	Erasmus Medical Center	Rotterdam

Sponsors (1)

Lead Sponsor	Collaborator
Foundation for Liver Research

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCV RNA suppression of 360 mug peginterferon alfa-2a QW, 9 MU interferon alfa-2a daily or 4,5 interferon alfa-2a daily in combination with 180 mug peginterferon alfa-2a QW		week 4
Secondary	To compare the virological breakthrough/relapse rate after dose adjustments (at 4,24,72) weeks.		week 4, 24 and 72
Secondary	To compare the sustained virological response rate at 24 weeks after end of treatment.		week 24 follow up